October 2022
Vol 8 | Issue 590

Q&A with John Hall Molecular of International Research, Inc.

VIce President Research and Development

Principal Series:

Molecular International Research Inc. is a small biotech company in New York City that has researched and patented a radically new anti-cancer and anti-inflammatory drug. The drug selectively kills tumor cells without systemic toxicity. Efficacy and safety co-exist in our drug which will make a break from the common apprehension that cancer treatment can be as dangerous to patients as the cancer itself. The drug works for treatment against most kinds of cancer and synergizes with mainstream therapies which will promote adoption by the pharmaceutical and healthcare industries. Initial valuation of the patent focused on three applications: pancreatic cancer, lung cancer and inflammation. For pancreatic cancer, conservative assumptions (e.g., 15% market share) are behind the Fair Market Value of $278 million. Additional applications increase the value of the patent significantly.

Join us for a private Family Office Insights featuring biotech inventor and executive, John Hall PhD of Molecular International Research Inc. MIR has created a new method for cancer treatment that solves the longstanding failures of conventional chemotherapy. Investors are invited to learn about this landmark invention and to consider investing to fund the transition from patent to human clinical trials. The goal of this critical next step in drug development is an Investigational New Drug Application (IND) to the FDA.

October 21, 2022 at 11:15am-12:15pm EST
RSVP & Confirmation Required

Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com

Has your approach to cancer already been exploited?

DNA damage that is specific to cancer has been scientifically established, but this is the first time the damaged structure has been the focus of anti-cancer drug development.

What does your drug do when it enters a normal cell?

If there is inflammation in the cell, it can function as an anti-inflammatory.

What is your strategy for drug development?

Conduct the research and toxicology studies that enable human clinical trials. Partner with a pharmaceutical company for licensing or acquisition. Conduct human clinical trials with cancer patients. Obtain drug approval from the FDA.

John Hall Molecular of International Research, Inc.

John Hall was born and raised in Princeton. He was a graduate fellow at Princeton University in Biochemistry, and he completed his PhD at New York University Medical Center, in the Department of Biochemistry. John was appointed to the faculty at Rockefeller University, in Cell Biology. His research focused on microtubule organizing centers, structures critical to the cell division process that is dysregulated in cancer. He served as President and CEO of Motility Research Corporation and is now Vice President for Research and Development at Molecular International Research, Inc. In addition to his talent for developing intellectual property, his expertise spans basic research, applied biomedical research, and clinical research in human trials.

Contact John: john@molecularny.com